journal article·2013Open access

Selective delivery of an anticancer drug with aptamer-functionalized liposomes to breast cancer cells in vitro and in vivo

Hang Xing, Li Tang, Xujuan Yang, Kevin Hwang, Wendan Wang, Qian Yin, Ngo Yin Wong, Lawrence W. Dobrucki, Norio Yasui, John A. Katzenellenbogen, William G. Helferich, Jianjun Cheng, Yi Lu

Journal of Materials Chemistry B· Volume 1· Issue 39

Abstract

Selective targeting of cancer cells is a critical step in cancer diagnosis and therapy. To address this need, DNA aptamers have attracted significant attention as possible targeting ligands. However, while their use in targeting cancer cells in vitro has been reported, their effectiveness has rarely been established in vivo. Here we report the development of a liposomal drug delivery system for targeted anticancer chemotherapy. Liposomes were prepared containing doxorubicin as a payload, and functionalized with AS1411, a DNA aptamer with strong binding affinity for nucleolin. AS1411 aptamer-functionalized liposomes increased cellular internalization and cytotoxicity to MCF-7 breast cancer cells as compared to non-targeting liposomes. Furthermore, targeted liposomal doxorubicin improved antitumor efficacy against xenograft MCF-7 breast tumors in athymic nude mice, attributable to their enhanced tumor tissue penetration. This study suggests that AS1411 aptamer-functionalized liposomes can recognize nucleolin overexpressed on MCF-7 cell surface, and therefore enable drug delivery with high specificity.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Advanced biosensing and bioanalysis techniques · RNA Interference and Gene Delivery · DNA and Nucleic Acid Chemistry

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (48)

Show source-provided references
1. Cheng · Biomaterials · 2007 · 28 · 86910.1016/j.biomaterials.2006.09.047 ↗
2. Peer · Nat. Nanotechnol. · 2007 · 2 · 75110.1038/nnano.2007.387 ↗
3. Aryal · ACS Nano · 2010 · 4 · 25110.1021/nn9014032 ↗
4. Kim · Mol. Pharmaceutics · 2011 · 8 · 195510.1021/mp100460h ↗
5. Zhu · Chem. Rev. · 2012 · 112 · 468710.1021/cr200263w ↗
6. Alley · Curr. Opin. Chem. Biol. · 2010 · 14 · 52910.1016/j.cbpa.2010.06.170 ↗
7. Yang · Nanoscale · 2013 · 5 · 23110.1039/C2NR32835F ↗
8. Reubi · Endocr. Rev. · 2003 · 24 · 38910.1210/er.2002-0007 ↗
9. Schrama · Nat. Rev. Drug Discovery · 2006 · 5 · 14710.1038/nrd1957 ↗
10. Zhang · Nat. Rev. Cancer · 2009 · 9 · 2810.1038/nrc2559 ↗
11. Gupta · Nanomedicine · 2007 · 2 · 2310.2217/17435889.2.1.23 ↗
12. Lammers · Acc. Chem. Res. · 2011 · 44 · 102910.1021/ar200019c ↗
13. Sapra · Prog. Lipid Res. · 2003 · 42 · 43910.1016/S0163-7827(03)00032-8 ↗
14. Keefe · Nat. Rev. Drug Discovery · 2010 · 9 · 53710.1038/nrd3141 ↗
15. Shangguan · Proc. Natl. Acad. Sci. U. S. A. · 2006 · 103 · 1183810.1073/pnas.0602615103 ↗
16. Farokhzad · Proc. Natl. Acad. Sci. U. S. A. · 2006 · 103 · 631510.1073/pnas.0601755103 ↗
17. Guo · Biomaterials · 2011 · 32 · 801010.1016/j.biomaterials.2011.07.004 ↗
18. Zhao · Angew. Chem., Int. Ed. · 2008 · 47 · 633010.1002/anie.200705982 ↗
19. Liu · Chem. Rev. · 2009 · 109 · 194810.1021/cr030183i ↗
20. Cho · Annu. Rev. Anal. Chem. · 2009 · 2 · 24110.1146/annurev.anchem.1.031207.112851 ↗
21. Li · Acc. Chem. Res. · 2010 · 43 · 63110.1021/ar900245u ↗
22. Oh · Proc. Natl. Acad. Sci. U. S. A. · 2010 · 107 · 1405310.1073/pnas.1009172107 ↗
23. Ray · Pharmaceuticals · 2010 · 3 · 176110.3390/ph3061761 ↗
24. Rosi · Chem. Rev. · 2005 · 105 · 154710.1021/cr030067f ↗
25. Dave · Adv. Mater. · 2011 · 23 · 318210.1002/adma.201101086 ↗
26. Cao · Angew. Chem., Int. Ed. · 2009 · 48 · 649410.1002/anie.200901452 ↗
27. Kaneda · Adv. Drug Delivery Rev. · 2000 · 43 · 19710.1016/S0169-409X(00)00069-7 ↗
28. Schafer · Biomaterials · 2010 · 31 · 689210.1016/j.biomaterials.2010.05.043 ↗
29. Maeda · J. Controlled Release · 2000 · 65 · 27110.1016/S0168-3659(99)00248-5 ↗
30. Derenzini · Lab. Invest. · 1995 · 73 · 497
31. Dapic · Nucleic Acids Res. · 2003 · 31 · 209710.1093/nar/gkg316 ↗
32. Otake · Blood · 2007 · 109 · 306910.1182/blood-2006-08-043257 ↗
33. Soundararajan · Cancer Res. · 2008 · 68 · 235810.1158/0008-5472.CAN-07-5723 ↗
34. Bates · Exp. Mol. Pathol. · 2009 · 86 · 15110.1016/j.yexmp.2009.01.004 ↗
35. Ireson · Mol. Cancer Ther. · 2006 · 5 · 295710.1158/1535-7163.MCT-06-0172 ↗
36. Park · Clin. Cancer Res. · 2002 · 8 · 1172
37. Barenholz · J. Controlled Release · 2012 · 160 · 11710.1016/j.jconrel.2012.03.020 ↗
38. Woodle · Biochim. Biophys. Acta · 1992 · 1113 · 17110.1016/0304-4157(92)90038-C ↗
39. Drummond · Pharmacol. Rev. · 1999 · 51 · 691
40. Bates · J. Biol. Chem. · 1999 · 274 · 2636910.1074/jbc.274.37.26369 ↗
41. Dapic · Biochemistry · 2002 · 41 · 367610.1021/bi0119520 ↗
42. Osborne · Cancer Res. · 1985 · 45 · 584
43. Low · Acc. Chem. Res. · 2008 · 41 · 12010.1021/ar7000815 ↗
44. Kirpotin · Cancer Res. · 2006 · 66 · 673210.1158/0008-5472.CAN-05-4199 ↗
45. Choi · Proc. Natl. Acad. Sci. U. S. A. · 2010 · 107 · 123510.1073/pnas.0914140107 ↗
46. Martin-Kleiner · Immunopharmacol. Immunotoxicol. · 2006 · 28 · 41110.1080/08923970600927520 ↗
47. Reeves · J. Nutr. · 1993 · 123 · 193910.1093/jn/123.11.1939 ↗
48. Ju · Cancer Res. · 2002 · 62 · 2474